Apollo Hospitals Q1FY27 Revenue Up 21% to ₹70,435 Cr; PAT Grows 34% to ₹5,805 Cr
Apollo Hospitals reported Q1 FY27 consolidated revenue of ₹70,435 crore (up 21% YoY) and PAT of ₹5,805 crore (up 34% YoY). Healthcare Services revenue grew 22% to ₹35,670 crore. Apollo HealthCo revenue increased 22% to ₹29,770 crore, with Apollo 24/7 GMV up 23% to ₹5,351 crore. The company is proceeding with the composite scheme for Apollo HealthCo, targeting listing by Q4 FY27.
The announcement includes significant financial results (revenue, PAT growth) and strategic updates like the composite scheme for Apollo HealthCo and its potential listing, which are material events for investors.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, indicating positive financial performance. Expansion in healthcare services and growth in digital health initiatives also contribute to a positive outlook.
Apollo Hospitals Enterprise Limited announced its financial results for the first quarter of FY27, reporting a consolidated revenue of ₹70,435 crore, an increase of 21% year-on-year. EBITDA grew by 28% to ₹10,920 crore, and Profit After Tax (PAT) saw a significant jump of 34% to ₹5,805 crore.
The Healthcare Services segment revenue grew by 22% to ₹35,670 crore, driven by a 13% increase in inpatient volume and an 8% rise in average revenue per inpatient. The company commissioned five new hospitals in the last two quarters, adding approximately 1,000 census beds. The EBITDA margin for established units stood at 25.9%.
Apollo HealthCo, the digital health and pharmacy distribution arm, reported a revenue growth of 22% to ₹29,770 crore. The digital platform, Apollo 24/7, saw a 23% year-on-year growth in Gross Merchandise Value (GMV) to ₹5,351 crore in Q1 FY27. The digital cash loss was reduced to ₹97 million in Q1 FY27, a significant reduction from the previous year.
The company also provided an update on its composite scheme for Apollo HealthCo, which involves the demerger of its omni-channel pharmacy distribution and digital platform, along with the remote telehealth division, into a new company. This new entity is expected to be listed by Q4 FY27.
Apollo Hospitals Enterprise Limited also highlighted several clinical updates and new initiatives, including the recognition of Apollo Children’s Hospital, Chennai, among the World’s Best Hospitals 2026, and an MoU with ePlane Company to explore electric air ambulances.
What to do with a filing like this
Apollo Hospitals Enterprise Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Apollo Hospitals Enterprise Limited. Read the original for the full detail.